N2-OH-PhIP is a PhIP metabolite.

PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively.

Nimucitinib is a Janus kinase (JAK) inhibitor.

JP-153 (JP153) is a novel small molecule targets the Src-FAK-Paxillin signaling, inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) in RECs; potently inhibits VEGF-induced proliferation and migration, inhibits retinal neovascularization in the murine oxygen-induced retinopathy model.

BRD-K56819078 is a small-molecule senolytics and significantly decreases senescent cell burden and mRNA expression of senescence-associated genes in the kidneys of aged mices.

GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

Pomalidomide-piperazine is an active compound that can be used to synthesis the E3 ligand for PROTAC.

HPPE is a specific nonelectrophilic and physiological Bach1 inhibitor via heme-binding sites of Bach1 protein, derepresses Bach1-mediated repression.HPPE induces up-regulation of Hmox1 mRNA is mediated by Bach1 inhibition in vivo.

Selective urotensin-II (UT) receptor antagonist (Ki values are 61, 17, 30, 65 and 56 nM at human, monkey, cat, rat and mouse receptors respectively). Inhibits U-II-induced intracellular Ca2+ mobilization (IC50 = 180 nM) and antagonizes the contractile act

NF-κΒ activator 1 is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD) 2 mRNA expression.

BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM.

ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor. ThioLox shows anti-inflammatory and neuroprotective properties.

CAY10462 is the hydrochloride salt of CAY10434 and selective inhibitor of the 20-HETE synthase CYP4A11 exhibiting an IC50 of 8.8 nM when tested in human renal microsomes.4 CAY10434 is nearly 200 times less potent as an inhibitor of 1A, 1C, and 3A CYP450.

Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM).

J 3-54 , also known as LSD1-IN-24, is a selective LSD1 inhibitor with IC50 = 0.247 μM. VUN34592 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research.

DKI5, also known as (E)-N’-benzylidenehydrazinecarbothiohydrazide, is a LOX-1 inhibitor with an IC50 value of 22.5 μM. DKI5 strongly inhibits lipid peroxidation.

HUN39963, also known as LDH-IN-2 is an inhibitor of glycolate oxidase. This compound was first reported in J Med Chem.

VUN28691, also known as p38α inhibitor 3, is a p38α inhibitor for treatment of p38-α kinase-mediated conditions.

GSK3β Inhibitor II, also known as KIN 001-042, also known as GSK-3β Inhibitor II, is a GSK-3β inhibitor.

CUN11141, also known as BRD4 Inhibitor-20, is a potent orally active bromodomain protein 4 (BRD4) inhibitor. It can be used for the research of kinds of cancer, such as colon cancer.

ZVN26391, also known as NLRP3-IN-10, is a IL-1β inhibitor for the treatment of inflammation and inflammation-related disease (neurogenic inflammation, Alzheimer disease, etc.).

WAY-299838 is a useful chemical agent for chemical synthesis of hypoxia-inducible factor-1 inhibitor.

RXN00442, also known as EGFR-IN-11, is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI). This compound was first reported in Eur J Med Chem.

WAY-658513 is a multiple kinase inhbitor. WAY658513 was shown to inhibit ROCK I, ERK2, GSK3, and PKA with Ki <1 μM.

NSC321039, also known as hMAO-B-IN-4, is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value of 0.067 μM.

BDTX-1535 is a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).

Moracin C is a phenolic compound isolated from Artocarpus heterophyllus. Moracin C suppresses Lipopolysaccharide-Activated Inflammatory Responses in Murine Raw264.7 Macrophages.

CPPHA is a selective positive allosteric modulator of mGluR5 receptor.

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.